- Home
- ATYR
as 12-20-2024 3:31pm EST
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 228.1M | IPO Year: | 2015 |
| Target Price: | $19.25 | AVG Volume (30 days): | 832.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.34 - $3.80 | Next Earning Date: | 11-07-2024 |
| Revenue: | $235,000 | Revenue Growth: | -97.81% |
| Revenue Growth (this year): | -28.66% | Revenue Growth (next year): | 1200.54% |
Latest aTyr Pharma Inc. Common Stock News
ATYR Breaking Stock News: Dive into ATYR Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Exploring Three High Growth Tech Stocks In The United States
Simply Wall St.
3 days ago
aTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional investors who own 57%
GlobeNewswire
5 days ago
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
10 days ago
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
GlobeNewswire
12 days ago
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
GlobeNewswire
13 days ago
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
GlobeNewswire
a month ago
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
GlobeNewswire
a month ago
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
Compare ATYR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATYR aTyr Pharma Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.